Esperion Q3 revenue up 69% on prescription volumes

Esperion Therapeutics

06/11/2025 11:08

Overview

Esperion Q3 2025 total revenue grows 69% yr/yr to $87.3 mln

Net income for Q3 missed analyst expectations

Reached settlement with Dr. Reddy's to delay generics until 2040

Outlook

Esperion expects sustainable profitability beginning in Q1 2026

Company reiterates 2025 operating expenses forecast of $215 mln to $235 mln

Esperion anticipates bempedoic acid inclusion in U.S. guidelines in early 2026

Result Drivers

U.S. PRESCRIPTION VOLUME - Increased U.S. prescription volume and expanded payer coverage drove revenue growth

SETTLEMENT AGREEMENT - Settlement with Dr. Reddy's prevents generic competition until 2040, supporting market leadership

GUIDELINE INCLUSION - Bempedoic acid's inclusion in European guidelines expected to boost utilization

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$40.66 mln
Q3 Net Income
Miss
-$31.33 mln
-$14.50 mln (5 Analysts)
Q3 Operating Income
Miss
-$9.96 mln
-$1.53 mln (4 Analysts)
Q3 Basic EPS
-$0.16
Q3 Operating Expenses
$97.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Esperion Therapeutics Inc is $4.00, about 26.5% above its November 5 closing price of $2.94

Press Release: ID:nGNX5yQYN5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)